New combo aims to keep lymphoma in check after CAR-T
NCT ID NCT07198373
First seen Nov 01, 2025 · Last updated May 31, 2026 · Updated 41 times
Summary
This study tests whether taking zanubrutinib (a targeted pill) after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults who have already had or are about to have CAR-T therapy will take zanubrutinib as a maintenance treatment. The main goal is to see how many patients remain cancer-free two years later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.